Trading Signals: MRTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Fri. Dec. 22, 2023)(Mirati Therapeutics Inc)
| MRTX latest price $22.1800 (2.26%) ($21.1000 - $22.8800) on Fri. Aug. 21, 2015. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 3.49% (three month average) | | RSI | 50 | | Latest Price | $22.1800(2.26%) | | Stocks Behave Similarly | Similar Stock List | | Daily Trend | MRTX declines -0.3% a day on average for past five trading days. | | Market Behavior | Broad based sell-off for large cap. Value stock sell-off for small cap. | | Correlated ETFs | Broad market will support MRTX advance at 0% a week (0% probability)
IBB(8%) XBI(8%) XLV(8%) QQQ(7%) EEM(6%) | | Factors Impacting MRTX price | MRTX will decline at least -1.745% in a week (0% probabilities).
IWN(-5%) BNDX(-5%) IWO(-4%) VIXM(-3%) TLT(-2%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.745% (StdDev 3.49%) | | Hourly BBV | 0 () | | Intraday Trend | 5.1% | | | | | |
|
| 5 Day Moving Average | $22.79(-2.68%) | | 10 Day Moving Average | $22.75(-2.51%) | | 20 Day Moving Average | $0(0%) | | To recent high | -7.2% | | To recent low | 2.3% | | Market Cap | $987m | | | | | | |
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA. |